Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6852950 | PMC |
| http://dx.doi.org/10.1186/s13075-019-2028-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Infliximab biosimilar-induced lupus nephritis: A case report.
Mod Rheumatol Case Rep
December 2023
Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
We present a case of microhematuria, proteinuria and hypocomplementemia which developed in a 55-year-old female who was being treated with an infliximab biosimilar for rheumatoid arthritis. Renal biopsy showed lupus nephritis (ISN/RPS classification class IV + V). Treatment with the infliximab biosimilar was discontinued, and treatment with prednisolone, hydroxychloroquine and abatacept was started, resulting in clinical remission of lupus nephritis and RA.
View Article and Find Full Text PDFLupus Cardiomyopathy and Nephritis Associated With Adalimumab and Cytomegalovirus Infection in a Patient With Seronegative Rheumatoid Arthritis: A Case of Rhupus Syndrome.
Cureus
February 2023
Infectious Diseases, MetroWest Medical Center, Tufts University School of Medicine, Framingham, USA.
Article Synopsis
- Tumor necrosis factor-alpha (TNF-α) inhibitors can lead to a lupus-like condition called anti-TNF-α-induced lupus (ATIL), and cytomegalovirus (CMV) infections may worsen lupus symptoms.
- A case study reports a 38-year-old woman with a history of seronegative rheumatoid arthritis who developed severe systemic lupus erythematosus (SLE) after using adalimumab during a CMV infection, presenting with serious symptoms like lupus nephritis and cardiomyopathy.
- Treatment involved stopping adalimumab and using aggressive steroid therapy alongside medications like prednisone, mycophenolate mofetil, and hydroxychloroquine, highlighting the potential risks for patients with ser
Anti-TNF-alpha-induced lupus in patients with non-infectious uveitis.
Eur J Ophthalmol
November 2021
Clínic Institute of Ophthalmology, 16493Hospital Clinic, Barcelona, Spain.
Article Synopsis
- Anti-TNF-α-induced lupus (ATIL) is a rare form of drug-induced lupus that can occur in patients undergoing anti-TNF-α therapy, particularly those with non-infectious uveitis (NIU).
- The study presents three cases of patients who developed symptoms like positive antinuclear antibodies (ANA), arthritis, and skin lesions after starting adalimumab, which resolved upon withdrawal of the medication.
- The findings suggest common characteristics among these cases, such as the onset of symptoms linked to anti-TNF-α treatment and a review of existing literature supports their classification within ATIL.
Antitumor Necrosis Factor-Alpha (TNF-) Infliximab-Induced Pleural Effusion and Pericarditis in Crohn's Disease.
Case Rep Pediatr
July 2021
Department of Pediatric Gastroenterology, Hepatology and Nutrition, Nicklaus Children's Hospital, Miami, FL, USA.
Crohn's disease (CD) is a chronic inflammatory disease that can be associated with intestinal and extraintestinal manifestations. Some patients are treated with infliximab, an antitumor necrosis factor-alpha (TNF-) agent, to help them achieve and maintain clinical and biochemical remission. However, some patients with CD can present severe adverse effects such as drug-induced lupus and rarely present with pleural space and pericardium involvement.
View Article and Find Full Text PDFClinical features of tumor necrosis factor-α-inhibitor induced chilblain lupus: A case series.
JAAD Case Rep
June 2021
Department of Dermatology, University of Wisconsin Hospital and Clinics, Madison, Wisconsin.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!